AB013. A pivotal phase 2 trial to compare PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), in combination with an immune checkpoint inhibitor (ICI) and ICI alone, for the treatment of recurrent or metastatic thymic epithelial carcinoma (TEC)

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC12529541 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature